Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk
Editorial Group: Cochrane Haematological Malignancies Group
Published Online: 19 OCT 2005
Assessed as up-to-date: 17 AUG 2005
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Franklin J, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003187. DOI: 10.1002/14651858.CD003187.pub2.
- Publication Status: Edited (no change to conclusions)
- Published Online: 19 OCT 2005
This article has been cited by:
- 1Declining Use of Radiotherapy in Stage I and II Hodgkin’s Disease and Its Effect on Survival and Secondary Malignancies, International Journal of Radiation Oncology*Biology*Physics, 2012, 82, 2, 619, , , ,
- 3The Epidemiology of Myelodysplastic Syndromes, Hematology/Oncology Clinics of North America, 2010, 24, 2, 287,
- 4Involved-Node and Involved-Field Volumetric Modulated Arc vs. Fixed Beam Intensity-Modulated Radiotherapy for Female Patients With Early-Stage Supra-Diaphragmatic Hodgkin Lymphoma: A Comparative Planning Study, International Journal of Radiation Oncology*Biology*Physics, 2009, 75, 5, 1578, , , ,
- 5Do We Need an Early Unfavorable (Intermediate) Stage of Hodgkin's Lymphoma?, Hematology/Oncology Clinics of North America, 2007, 21, 5, 881, ,